ximelagatran

(redirected from Exanta)

ximelagatran

An oral direct thrombin inhibitor drug used as an anticoagulant alternative to warfarin in the management of thromboembolism. In late 2004 the American FDA rejected an application for approval of this drug on the grounds of liver toxicity.
References in periodicals archive ?
Examples of such occurrences taken from the sample used in this study include excerpts like "As any scientist can tell you, those rare moments of success are often woven together with countless moments of disappointment" and "We also experienced disappointments with [drug projects] Exanta and Iressa and some difficult market conditions." In turn, these collective emotions can impact work outcomes (George & Brief, 1992).
Astrazeneca has called time on the development of its blood thinning drug Exanta after long-term studies uncovered a report of serious liver damage.
ASTRAZENECA yesterday called time on the development of its blood thinning drug Exanta after long-term studies uncovered a report of serious liver damage.
Astra has been trying to bolster its new drugs pipeline after US regulators rejected its blood-thinning drug Exanta last year.
In December, following the failure of blood thinning drug Exanta to win FDA approval, AstraZeneca announced it would accelerate changes at its clinical and regulatory programs.
Clinical trial results for a new, oral antithrombotic, ximelagatran (Exanta) generated a lot of anticipation, but the Food and Drug Administration rejected its licensing application last October due to safety concerns.
Among its recent woes, Astra has seen blood-thinning drug Exanta provisionally rejected by US regulators and an admission that its Iressa cancer treatment was unable to prolong the life of patients significantly.
Called Exanta, the drug was billed as treatment to stop blood-clotting and help prevent strokes.
The US Food and Drug Administration told the company they needed to provide more data on Exanta amid fears the blood-thinning drug could cause liver failure in patients in the long term.
Pharmaceuticals companies were in focus as AstraZeneca suffered a vote by the US Food and Drug Advisory committee against approval of one of its key drugs, Exanta. The stock lost more than 6pc of its value - off 156p to 2294p making it the heaviest Footsie faller.
Key upcoming launches are Iressa, an anticancer agent; Crestor, a lipid-lowering medication; and Exanta for stroke prevention.